<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35203674</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2227-9059</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>16</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biomedicines</Title>
          <ISOAbbreviation>Biomedicines</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Minimum Effective Dose of DPP-4 Inhibitors for Treating Early Stages of Diabetic Retinopathy in an Experimental Model.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">465</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines10020465</ELocationID>
        <Abstract>
          <AbstractText>The neurovascular unit (NVU) plays an essential role in the development of diabetic retinopathy (DR). We previously reported that the topical administration (eye drops) of sitagliptin and saxagliptin, two dipeptidyl peptidase-4 inhibitors (DPP-4i), prevents retinal neurodegeneration and vascular leakage in db/db mice. The aim of the present study is to evaluate the minimum effective dose of the topical administration of these DPP-4i. For this purpose, sitagliptin and saxagliptin were tested at different concentrations (sitagliptin: 1 mg/mL, 5 and 10 mg/mL, twice per day; saxagliptin: 1 and 10 mg/mL, once or twice per day) in db/db mice. As end points of efficacy, the hallmarks of NVU impairment were evaluated: reactive gliosis, neural apoptosis, and vascular leakage. These parameters were assessed by immunohistochemistry, cell counting, and the Evans blue method, respectively. Our results demonstrated that the minimum effective dose is 5 mg/mL twice per day for sitagliptin, and 10 mg/mL twice per day for saxagliptin. In conclusion, this study provides useful results for the design of future preclinical regulatory studies and for planning clinical trials.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bogdanov</LastName>
            <ForeName>Patricia</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0003-0669-4958</Identifier>
            <AffiliationInfo>
              <Affiliation>Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, 08035 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramos</LastName>
            <ForeName>Hugo</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0001-6443-7576</Identifier>
            <AffiliationInfo>
              <Affiliation>Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, 08035 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Valeri</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Unit of High Technology, Vall d'Hebron Research Institute, 08035 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deàs-Just</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-3129-6313</Identifier>
            <AffiliationInfo>
              <Affiliation>Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, 08035 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huerta</LastName>
            <ForeName>Jordi</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-9908-8051</Identifier>
            <AffiliationInfo>
              <Affiliation>Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, 08035 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simó</LastName>
            <ForeName>Rafael</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0003-0475-3096</Identifier>
            <AffiliationInfo>
              <Affiliation>Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, 08035 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hernández</LastName>
            <ForeName>Cristina</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-3109-1721</Identifier>
            <AffiliationInfo>
              <Affiliation>Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, 08035 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), 28029 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Biomedicines</MedlineTA>
        <NlmUniqueID>101691304</NlmUniqueID>
        <ISSNLinking>2227-9059</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">db/db mice</Keyword>
        <Keyword MajorTopicYN="N">diabetic retinopathy</Keyword>
        <Keyword MajorTopicYN="N">dipeptidyl peptidase-4 inhibitors</Keyword>
        <Keyword MajorTopicYN="N">experimental diabetes</Keyword>
        <Keyword MajorTopicYN="N">neurovascular unit</Keyword>
        <Keyword MajorTopicYN="N">retinal neurodegeneration</Keyword>
        <Keyword MajorTopicYN="N">saxagliptin</Keyword>
        <Keyword MajorTopicYN="N">sitagliptin</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest. Vall d’Hebron Research Institute holds intellectual property related to the use of ocular DPP-4 inhibitors to treat diabetic retinopathy. No other potential conflict of interest relevant to this article were reported.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>1</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35203674</ArticleId>
        <ArticleId IdType="pmc">PMC8962353</ArticleId>
        <ArticleId IdType="doi">10.3390/biomedicines10020465</ArticleId>
        <ArticleId IdType="pii">biomedicines10020465</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Leasher J.L., Bourne R.R., Flaxman S.R., Jonas J.B., Keeffe J., Naidoo K., Pesudovs K., Price H., White R.A., Wong T.Y., et al.  Vision Loss Expert Group of the Global Burden of Disease Study. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: A meta-analysis from 1990 to 2010. Diabetes Care. 2016;39:1643–1649. doi: 10.2337/dc15-2171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc15-2171</ArticleId>
            <ArticleId IdType="pubmed">27555623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teo Z.L., Tham Y.C., Yu M., Chee M.L., Rim T.H., Cheung N., Bikbov M.M., Wang Y.X., Tang Y., Lu Y., et al.  Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology. 2021;128:1580–1591. doi: 10.1016/j.ophtha.2021.04.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2021.04.027</ArticleId>
            <ArticleId IdType="pubmed">33940045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong T.Y., Cheung C.M., Larsen M., Sharma S., Simó R. Diabetic retinopathy. Nat. Rev. Dis. Primers. 2016;17:16012. doi: 10.1038/nrdp.2016.12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2016.12</ArticleId>
            <ArticleId IdType="pubmed">27159554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simó R., Hernández C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog. Retin. Eye Res. 2015;48:160–180. doi: 10.1016/j.preteyeres.2015.04.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.preteyeres.2015.04.003</ArticleId>
            <ArticleId IdType="pubmed">25936649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simó R., Stitt A.W., Gardner T.W. Neurodegeneration in diabetic retinopathy: Does it really matter? Diabetologia. 2018;61:1902–1912. doi: 10.1007/s00125-018-4692-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00125-018-4692-1</ArticleId>
            <ArticleId IdType="pmc">PMC6096638</ArticleId>
            <ArticleId IdType="pubmed">30030554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simó R., Simó-Servat O., Bogdanov P., Hernández C. Neurovascular Unit: A New Target for Treating Early Stages of Diabetic Retinopathy. Pharmaceutics. 2021;13:1320.  doi: 10.3390/pharmaceutics13081320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pharmaceutics13081320</ArticleId>
            <ArticleId IdType="pmc">PMC8399715</ArticleId>
            <ArticleId IdType="pubmed">34452281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández C., Bogdanov P., Corraliza L., García-Ramírez M., Solà-Adell C., Arranz J.A., Arroba A.I., Valverde A.M., Simó R. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes. 2016;65:172–187. doi: 10.2337/db15-0443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db15-0443</ArticleId>
            <ArticleId IdType="pubmed">26384381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sampedro J., Bogdanov P., Ramos H., Solà-Adell C., Turch M., Valeri M., Simó-Servat O., Lagunas C., Simó R., Hernández C. New Insights into the Mechanisms of Action of Topical Administration of GLP-1 in an Experimental Model of Diabetic Retinopathy. J. Clin. Med. 2019;8:339.  doi: 10.3390/jcm8030339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm8030339</ArticleId>
            <ArticleId IdType="pmc">PMC6463072</ArticleId>
            <ArticleId IdType="pubmed">30862093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simó R., Bogdanov P., Ramos H., Huerta J., Simó-Servat O., Hernández C. Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes. Biomedicines. 2021;9:926.  doi: 10.3390/biomedicines9080926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biomedicines9080926</ArticleId>
            <ArticleId IdType="pmc">PMC8392846</ArticleId>
            <ArticleId IdType="pubmed">34440130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández C., García-Ramírez M., Corraliza L., Fernández-Carneado J., Farrera-Sinfreu J., Ponsati B., González-Rodríguez A.D., Valverde A.M., Simó R. Topical Administration of Somatostatin Prevents Retinal Neurodegeneration in Experimental Diabetes. Diabetes. 2013;62:2569–2578. doi: 10.2337/db12-0926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db12-0926</ArticleId>
            <ArticleId IdType="pmc">PMC3712066</ArticleId>
            <ArticleId IdType="pubmed">23474487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández C., Arroba A.I., Bogdanov P., Ramos H., Simó-Servat O., Simó R., Valverde A.M. Effect of Topical Administration of Somatostatin on Retinal Inflammation and Neurodegeneration in an Experimental Model of Diabetes. J. Clin. Med. 2020;9:2579.  doi: 10.3390/jcm9082579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm9082579</ArticleId>
            <ArticleId IdType="pmc">PMC7463891</ArticleId>
            <ArticleId IdType="pubmed">32784955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Leo L.F., McGregor C., Grivitishvili A., Barnstable C.J., Tombran-Tink J. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice. Mol. Med. 2012;18:1387–1401. doi: 10.2119/molmed.2012.00008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2119/molmed.2012.00008</ArticleId>
            <ArticleId IdType="pmc">PMC3533643</ArticleId>
            <ArticleId IdType="pubmed">23019073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández C., Bogdanov P., Solà-Adell C., Sampedro J., Valeri M., Genís X., Simó-Servat O., García-Ramírez M., Simó R. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. Diabetologia. 2017;60:2285–2298. doi: 10.1007/s00125-017-4388-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00125-017-4388-y</ArticleId>
            <ArticleId IdType="pubmed">28779212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson P.J., Watts H., Hille C., Philpott K., Clark P., Gentleman M.C.S., Jen L.-S. Glial and endothelial blood-retinal barrier responses to amyloid-beta in the neural retina of the rat. Clin. Ophthalmol. 2008;2:801–816. doi: 10.2147/OPTH.S3967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OPTH.S3967</ArticleId>
            <ArticleId IdType="pmc">PMC2699783</ArticleId>
            <ArticleId IdType="pubmed">19668434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golightly L.K., Drayna C.C., McDermott M.T. Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors. Clin. Pharmacokinet. 2012;51:501–514. doi: 10.1007/BF03261927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03261927</ArticleId>
            <ArticleId IdType="pubmed">22686547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun J.K., Aiello L.P., Abràmoff M.D., Antonetti D.A., Dutta S., Pragnell M., Levine S.R., Gardner T.W. Updating the Staging System for Diabetic Retinal Disease. Ophthalmology. 2021;128:490–493. doi: 10.1016/j.ophtha.2020.10.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2020.10.008</ArticleId>
            <ArticleId IdType="pmc">PMC8378594</ArticleId>
            <ArticleId IdType="pubmed">33218709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solomon S.D., Chew E., Duh E.J., Sobrin L., Sun J.K., VanderBeek B.L., Wykoff C.C., Gardner T.W. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40:412–418. doi: 10.2337/dc16-2641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc16-2641</ArticleId>
            <ArticleId IdType="pmc">PMC5402875</ArticleId>
            <ArticleId IdType="pubmed">28223445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thagaard M.S., Vergmann A.S., Grauslund J. Topical treatment of diabetic retinopathy: A systematic review. Acta Ophthalmol. 2021;100:136–147. doi: 10.1111/aos.14912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/aos.14912</ArticleId>
            <ArticleId IdType="pubmed">34096180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dietrich N., Kolibabka M., Busch S., Bugert P., Kaiser U., Lin J., Fleming T., Morcos M., Klein T., Schlotterer A., et al.  The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy. PLoS ONE. 2016;11:e0167853.  doi: 10.1371/journal.pone.0167853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0167853</ArticleId>
            <ArticleId IdType="pmc">PMC5152931</ArticleId>
            <ArticleId IdType="pubmed">27942008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang H., Li G., Zhao Y., Wang F., Gower E.W., Shi L., Wang T. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis. Diabetes Obes. Metab. 2018;20:1262–1279. doi: 10.1111/dom.13232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dom.13232</ArticleId>
            <ArticleId IdType="pubmed">29369494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung Y.R., Ha K.H., Kim H.C., Park S.J., Lee K., Kim D.J. Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study. Diabetes Metab. J. 2019;43:640–648. doi: 10.4093/dmj.2018.0137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4093/dmj.2018.0137</ArticleId>
            <ArticleId IdType="pmc">PMC6834833</ArticleId>
            <ArticleId IdType="pubmed">30877707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fura A., Khanna A., Vyas V., Koplowitz B., Chang S.Y., Caporuscio C., Boulton D.W., Christopher L.J., Chadwick K.D., Hamann L.G., et al.  Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab. Dispos. 2009;37:1164–1171. doi: 10.1124/dmd.108.026088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/dmd.108.026088</ArticleId>
            <ArticleId IdType="pubmed">19251818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuchs H., Binder R., Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm. Drug. Dispos. 2009;30:229–240. doi: 10.1002/bdd.662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bdd.662</ArticleId>
            <ArticleId IdType="pubmed">19562682</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
